Reckitt Benckiser Group/£RKT

07:00
09:10
11:15
13:25
15:30
1D1W1MYTD1Y5YMAX

About Reckitt Benckiser Group

Reckitt Benckiser Group is a British multinational consumer goods company headquartered in Slough, England. It operates within the health, hygiene, and home product categories. The company's key brands include Dettol, Lysol, Durex, and Nurofen, offering a wide range of products from disinfectants to pharmaceuticals. Founded in 1999 through the merger of Reckitt & Colman and Benckiser, the company has a significant global presence, with operations in over 60 countries. Reckitt Benckiser's strategic strength lies in its diversified product portfolio and strong brand recognition, which facilitate its competitive positioning in various consumer markets.

Ticker

£RKT

Primary listing

LSE

Employees

37,900

RKT Metrics

BasicAdvanced
£38B
31.29
£1.80
0.07
£2.06
3.66%

What the Analysts think about RKT

Analyst ratings (Buy, Hold, Sell) for Reckitt Benckiser Group stock.

Bulls say / Bears say

Reckitt sold a majority stake in its Essential Home business to Advent International for $4.8 billion, retaining a 30 % interest and earmarking $2.2 billion for a special dividend and share consolidation, sharpening its focus on high-margin core Powerbrands and enhancing shareholder returns (Reuters)
Emerging Markets net revenue grew 12.8 % on a like-for-like basis in H1 2025—driven by 7.1 % volume growth and 5.7 % price/mix improvement—buoying adjusted operating profit margin by 270 bps to 19.9 % and underscoring the strength of Reckitt’s global footprint (MarketScreener)
Core Reckitt’s Powerbrands delivered 5.3 % like-for-like net revenue growth in Q2 2025, exceeding expectations and prompting the company to raise its full-year Core LFL revenue growth guidance to above 4 % (WSJ)
Critics argue the Essential Home sale values the division at up to $4.8 billion—up to £1 billion below some expectations—while Reckitt retains a 30% stake, leaving the company exposed to ongoing underperformance and diluting the benefits of a clean exit (FT)
The Essential Home division saw a 7 % like-for-like net revenue decline to £482 million in Q1 2025, highlighting persistent weakness that led to its divestment and signaling challenges in Reckitt’s non-core portfolio (Reuters)
Reckitt’s Mead Johnson infant formula business remains under strategic review amid costly U.S. litigation and a prior $5 billion writedown, creating earnings volatility and uncertainty over the timing and proceeds of any disposal (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

RKT Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RKT Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £RKT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs